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Clin CancPurpose: The biological and clinical heterogeneity of chronic myelomonocytic leukemia features ren-
ders its classification difficult. Moreover, because of the limited knowledge of the mechanisms involved
in malignant evolution, chronic myelomonocytic leukemia remains a diagnostic and therapeutic chal-
lenge and a poor prognosis disease. We aimed to verify the biological and clinical significance of the
discrimination, based on the leukocyte count, between myelodysplastic chronic myelomonocytic leuke-
mia (MD-CMML) and myeloproliferative chronic myelomonocytic leukemia (MP-CMML).
Experimental Design: Peripheral blood samples from 22 patients classified as MD-CMML and 18 as
MP-CMML were collected at different time points during disease course, and patients' clinical charac-
teristics were examined. RAS mutational screening was done by sequencing and, for each substitution
identified, a highly selective allele-specific PCR was set up to screen all specimens.
Results: MP-CMML patients showed a significantly poorer survival (P = 0.003) and a higher frequen-
cy of RAS mutations (P = 0.033) by sequencing compared with MD-CMML. Overall, five MD-CMML
patients progressed to myeloproliferative disease: in two, allele-specific PCR unveiled low levels of the
RAS mutations predominating in the myeloproliferative phase at the time of myelodysplastic disease,
documenting for the first time the expansion of a RAS mutated clone in concomitance with chronic
myelomonocytic leukemia evolution. Moreover, one of the progressed patients harbored the FLT3-ITD
and two MP-CMML patients presented with the JAK2 V617F substitution. All these lesions were mutu-
ally exclusive.
Conclusions: Our results strongly suggest RAS mutations to function as a secondary event that con-
tributes to development of the chronic myelomonocytic leukemia variant with the poorer prognosis
(MP-CMML) and therefore advise their detection to be implemented in chronic myelomonocytic leu-
kemia diagnostics and monitoring. Clin Cancer Res; 16(8); 2246–56. ©2010 AACR.Chronic myelomonocytic leukemia is a rare malignan-
cy of the elderly whose diagnosis entails persistent abso-
lute monocytosis in the blood (monocytes, >1 × 109/L).
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clincancerres.aacrjDownloaded from and morphologic features, varying from mainly myelo-
dysplastic to predominantly myeloproliferative (1, 2).
Hence, chronic myelomonocytic leukemia nosology
has always represented a hurdle; the French American
Group (FAB) classification firstly categorized this dis-
order as a myelodysplastic syndrome (3) and then, in
1994, based on the WBC count threshold of 13 × 109/L,
proposed to discriminate between myelodysplastic
chronic myelomonocytic leukemia (MD-CMML, WBC,
<13 × 109/L) andmyeloproliferative chronic myelomono-
cytic leukemia (MP-CMML, WBC, ≥13 × 109/L; ref. 4). Yet,
the biological and clinical significance of this distinction
remains controversial because the two groups have been
variably associated with prognosis (5–10) and few cases
of MD-CMML progressing to MP-CMML have been re-
ported (1, 2, 8, 11); accordingly, this discrimination was
not acknowledged in the last WHO classification of
myeloid malignancies, in which chronic myelomonocytic
leukemia has been rather included in the new category
of the myelodysplastic syndrome/myeloproliferative neo-
plasms (12, 13). ciation for Cancer Research
 on October 8, 2012ournals.org
Translational Relevance
To date, chronic myelomonocytic leukemia remains
a diagnostic and therapeutic challenge, in most cases
with a dismal prognosis. Our findings support the
prognostic significance of the classification, based on
the leukocyte count, into myelodysplastic and myelo-
proliferative chronic myelomonocytic leukemia and
document for the first time the contribution of RAS
mutations to chronic myelomonocytic leukemia pro-
gression from myelodysplastic to myeloproliferative
phase. Our results strongly suggest these aberrations
to function as a secondary event that contributes to
the expansion of a malignant clone with proliferative
advantage. Therefore, we propose RAS mutational
screening by highly selective, yet simple and low-cost
allele-specific PCR, to be implemented as a standard in
chronic myelomonocytic leukemia diagnostics and
disease monitoring because patients harboring RAS
mutations are predicted to develop the disease pheno-
type with the worse prognosis (myeloproliferative
chronic myelomonocytic leukemia).
RAS Mutations in CMML
Published OnlineFirst April 14, 2010; DOI:10.1158/1078-0432.CCR-09-2112The high variability of the clinical presentation and
course of chronic myelomonocytic leukemia reflects the
heterogeneity of its pathogenetic features. Since, to date,
the recurrent mechanisms involved in its malignant evo-
lution have not been fully elucidated, chronic myelomo-
nocytic leukemia remains a diagnostic and therapeutic
challenge, in most cases with a dismal prognosis. Nota-
bly, among hematologic malignancies, chronic myelomo-
nocytic leukemia encounters the highest incidence of RAS
substitutions (up to 50%, usually in codons 12, 13, and
61 of NRAS and KRAS; ref. 14), which have been associ-
ated with features of cell proliferation and monocytosis
(1) and with shorter survival (15). Of note, a significant-
ly higher incidence of these mutations has been docu-
mented among MP-CMML than MD-CMML patients
(1, 14), and the expression of activated KRAS and NRAS
in murine bone marrow cells has been shown to rapidly
and efficiently induce a fatal myeloproliferative disease
resembling human chronic myelomonocytic leukemia
(16, 17). However, RAS mutations are not specific for
chronic myelomonocytic leukemia (18), and conversely,
other genetic lesions have been found in subsets of pa-
tients. For example, RUNX1 aberrations have been de-
tected in MD-CMML and MP-CMML patients, also in
concomitance with RAS mutations, suggesting implica-
tion of these abnormalities in the acquisition of myelo-
dysplastic features (14). More recently, mutations of the
putative tumor suppressor gene TET2 have been identi-
fied in a spectrum of myeloid malignancies (19–26), in-
cluding chronic myelomonocytic leukemia (21–23, 26),
MD-CMML and MP-CMML (26). Noteworthy, the ubi-
quitous nature of TET2 mutations suggests that they arewww.aacrjournals.org
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at least one additional contributing event is required to
determine the disease phenotype (19, 27). Other genetic
defects (i.e., FLT3-ITD and JAK2 V617F substitution; refs.
28–30) have been identified at a higher frequency among
MP-CMML than MD-CMML patients, in a manner
mutually exclusive with RAS mutations, and have been
shown to induce a chronic myelomonocytic leukemia-
like disease in mice (i.e., the FLT3-ITD and BID deletion;
refs. 28, 31), implying a role in the establishment of
myeloproliferation. Therefore, although a key role for
RAS mutations in chronic myelomonocytic leukemia
pathogenesis has been proposed, particularly in those
forms with a prominent proliferative component, no
straightforward conclusion has been definitely drawn.
Because its pathogenesis is mostly unknown, to date,
the only possible curative strategy for chronic myelomo-
nocytic leukemia remains allogeneic stem cell transplanta-
tion, which, however, may be applied only to a small
fraction of patients because of the advanced median age
of presentation (32). Hence, to improve patient outcome,
it is crucial to define molecular subtypes of chronic mye-
lomonocytic leukemia, which could possibly facilitate the
development of novel targeted agents.
In light of these issues, we aimed to investigate the bio-
logical and clinical significance of the discrimination be-
tween MD-CMML and MP-CMML. Our findings support
the prognostic significance of this distinction because
MP-CMML patients had a significantly shorter survival
than those with myelodysplastic disease. Moreover, we
document for the first time the expansion of a RAS-mutated
clone in concomitance with progression from MD-CMML
to MP-CMML, strongly suggesting these aberrations to
function as a secondary event that contributes to the ex-
pansion of a malignant clone with proliferative advantage.
Altogether, our results highlight the clinical relevance
of identifying chronic myelomonocytic leukemia pa-
tients harboring these aberrations because they are pre-
dicted to develop the disease phenotype with the worse
prognosis (MP-CMML).
Materials and Methods
Patients characteristics. Forty patients diagnosed with
chronic myelomonocytic leukemia were included in this
study between December 2002 and December 2008; ac-
cording to the FAB proposal (4), 22 were classified as
MD-CMML and 18 as MP-CMML. In addition, our series
included one patient (patient 38) who developed chronic
myelomonocytic leukemia rapidly progressing to the MP-
CMML, after achievement of complete remission from a
previously diagnosed Philadelphia-positive chronic mye-
logenous leukemia (CML). Clinical and laboratory charac-
teristics of patients are listed in Tables 1 and 2. Five
patients (patients 7, 8, 9, 31, and 33) initially presented
as MD-CMML and later on experienced evolution to mye-
loproliferative disease. Patients 24 and 30 were referred as
MP-CMML but had a previous history of MD-CMML.Clin Cancer Res; 16(8) April 15, 2010 2247
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2 71 M 10.3 3.6 46, XY
3 71 F 8.4 1.6 46, XX
4 64 M 4.5 1.6 46, XY
5 89 F 9.2 2.0 46, XX
6 74 F 3.9 1.1 46, XX
7* 69 F 12.3 3.3 46, XX
8* 73 F 7.6 2.7 46, XX
9* 77 M 7.6 1.8 46, XY
10 80 F 3.5 1.0 46, XX
11 64 F 10.1 1.3 46, XX
13 88 F 3.2 2.0 46, XX
15 82 F 5.2 1.9 46, XX
17 84 M 4.0 1.2 46, XY, del(20)(q11)
18 76 M 6.6 1.8 45, X,-Y
19 72 M 3.9 1.1 46, XY
20 70 F 6.0 2.2 n.a.
21 69 F 10.6 4.7 46, XX
26 66 F 4.6 1.3 46,XX
29† 71 M 5.3 1.8 46, XY
31* 79 M 6.0 1.4 46, XY
33*,‡ 59 F 11.4 1.1 46, XX
41 81 M 8.3 2.0 46, XYMP-CMML1§ 76 M 14.4 4.0 46, XY
12 80 F 13.4 4.8 46, XX14§ 69 M 9.4 2.0 46, XY, inv(9)(p11q12)16 68 M 13.4 3.6 46, XY22 70 M 39.5 2.2 46, XY23 70 M 13.9 2.3 46, XY24∥ 71 M 14.6 3.7 46, XY25 84 F 16.6 3.2 n.a.27§ 77 M 16.2 5.8 46, XY28 78 M 21.2 3.0 46, XY30∥ 74 F 30 7.6 n.a.32 83 F 13.7 2.3 46, XX34 79 M 15.3 4.1 n.a.35 79 M 21.5 6.1 n.a.36§ 68 M 22.8 3.1 n.a.37§ 72 M 39.4 5.7 46, XY39§ 73 M 23.9 3.7 46, XY40 79 M 14 1.8 46, XYCML38*,§ 69 M 88.3 3.5 t(9;22)(q34;q11)Abbreviations: Pt., patient; M, male; F, female; n.a., not available.
*Patients who later on developed MP-CMML.
†This patient 10 months after presentation displayed the trisomy of chromosome 8 (47, XY +8 [13] 46, XY [13]).
‡Thirty-six months after first presentation and in concomitance with development of acute myelogenous leukemia, this patient
displayed the following cytogenetics: 45, XX, del(6)(q22), -7, add(12)(p13).
§Patients under chemotherapy.
∥MP-CMML patients with a previous history of MD-CMML.ical Cancer Research
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 on October 8, 2012gFollow-up (mo)By seq By ASP By seq By ASPMD-CMML
2 WT WT WT (+11 mo) WT (+11 mo) MD-CMML; lost to follow-up 11
3 WT WT MD-CMML 82.5
4 WT WT MD-CMML 80
5 WT WT WT (+27 mo) WT (+27 mo) MD-CMML; lost to follow-up 35
6 WT WT MD-CMML 81
7 WT WT WT (+23 mo) WT (+23 mo) Progressed to MP-CMML;
deceased
268 WT N G60E N G60E
(+22 mo)N G60E
(+22 mo)Progressed to MP-CMML;
deceased259 WT WT WT (+23 mo) WT (+23 mo) Progressed to MP-CMML;
lost to follow-up3010 WT WT MD-CMML 76.5
11 WT WT MD-CMML 75
13 WT WT Lost to follow-up 0
15 WT WT Lost to follow-up 0
17 WT WT Deceased 40
18 WT WT MD-CMML 53
19 WT WT MD-CMML 58.5
20 WT WT MD-CMML 57.5
21 WT WT Deceased 42
26 WT WT MD-CMML 47
29 WT WT WT (+10 mo) WT (+10 mo) Progressed to AML;
deceased
1331* WT WT WT (+6 mo) WT (+6 mo) Progressed to MP-CMML
and then AML; deceased833 WT N G12D N G12D
(+13-18 mo)N G12D
(+13 mo)Progressed to MP-CMML
and then AML; deceased39.541 WT WT MD-CMML 13.5
MP-CMML1 WT WT Deceased 5
12 N G12D N G12D N G12D
(+19 mo)
N G12D
(+19 mo)MP-CMML† 73.514 N G12D N G12D N G12D (+8 mo) N G12D (+8 mo) Deceased 15
16 WT WT Deceased 24
22 WT N G12D Deceased 28
23‡ WT WT WT (+30 mo) WT (+30 mo) Deceased 48
24 WT WT N G12V
(+36 mo)
N G12V
(+27 mo)MP-CMML† 55.525 N G12D N G12D Deceased 12
27 WT WT Deceased 10
28 WT WT Deceased 2
30 K G12R K G12R Progressed to AML;
deceased
132 WT N G12D MP-CMML 41.5
34 WT WT MP-CMML 38
35‡ WT WT Deceased 2
36 WT WT Progressed to AML;
deceased
14(Continued on the following page)6(8) April 15, 2010 2249
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Published OnlineFirst April 14, 2010; DOI:10.1158/1078-0432.CCR-09-2112Sample collection and preparation. Overall, 62 peripheral
blood samples were obtained after informed consent.
Peripheral blood mononuclear cells were isolated by Hys-
topaque 1077 density gradient (Sigma). Genomic DNA
extraction was carried out by DNAzol (Molecular Research
Center, Inc.); RNA was isolated by TRIreagent (Sigma), and
cDNA was synthesized using oligo(dT)12-18 primers and
SuperScript II Reverse Transcriptase (Invitrogen) according
to the manufacturer's instructions.
Direct sequencing of KRAS and NRAS. Regions spanning
codons 12 to 13 (exon 1) and 61 (exon 2) of NRAS and
codons 12-13 (exon 1), 61 (exon 2), and 146 (exon 3;
refs. 14, 33) of KRAS were amplified by PCR using
M13-tailed primers starting from 200 ng of DNA (Sup-
plementary Table S1 and S2). Amplicons were purified
(MinElute QIAquick gel extraction kit, Qiagen) and auto-
matically sequenced (ABI PRISM 310 Genetic Analyzer,
Applied Biosystems) using the Big Dye Terminator Cycle
Sequencing Kit.
Construction of green fluorescent protein (GFP)–NRAS
chimeras. Primers for amplification of the entire human
NRAS coding sequence (GenBank NM_002524) were de-
signed as previously described (34), with minor modifi-
cations. Briefly, two nucleotides were added to the
forward primer to insert NRAS in frame with GFP, and
four and two excess nucleotides were added at the 5′ of
PstI and BamHI sites, respectively, to increase cleavage ef-
ficiency of endonucleases (Supplementary Table S1). The
sequence of the final construct was verified by sequencing
using the internal primer (NRAS coding sequence-
forward internal) specified in Supplementary Table S1.
PstI/BamHI-digested amplicons corresponding to the en-
tire coding sequence of NRAS wild type (WT), G12D,
and G60E were inserted into the PstI/BamHI-digested
pAcGFP-C1 vector (Clontech Laboratories, Inc.), leading
to a chimeric construct of GFP fused in frame to the 5′
end of NRAS. The resulting plasmids were subcloned into
Escherichia coli.Clin Cancer Res; 16(8) April 15, 2010
American Asso Copyright © 2010 
clincancerres.aacrjDownloaded from Transient transfection of NIH3T3 cells, confocal analysis,
and evaluation of Ras-GTP levels. NIH3T3 mouse fibro-
blasts were maintained in DMEM (Cambrex Corpora-
tion) supplemented with 10% of fetal bovine serum
(Sigma) and 1% of a penicillin/streptomycin solution
(Sigma). Cells were transiently transfected with 1 μg of
the pAcGFP-C1 vector, either empty or containing the
GFP-NRAS WT, G12D, or G60E constructs, using
Lipofectamine 2000 (Invitrogen) according to the manu-
facturer's instructions.
For confocal analysis, NIH3T3 cells were grown on four-
well glass chambers, transfected, fixed 48 h later with 4%
paraformaldehyde, permeabilized with 1% Triton X-100,
and incubated overnight with 1:50 Anti-Pan Ras Ab (Cal-
biochem). After 30 min of labeling with phycoerythrin,
cells were washed, mounted with cover glass, and ana-
lyzed by confocal microscopy.
For biochemical analysis, 48 h after transfection,
NIH3T3 cells were lysed to pull down the GTP-bound
Ras by affinity purification with the Raf-1RBD agarose
(Pierce Biotechnology, Inc.) following the manufacturer's
instructions. Whole cell extracts and pull-down superna-
tants were then separated on SDS-PAGE, and immuno-
blots were incubated overnight with the Anti-Pan Ras Ab
(Calbiochem).
Set up of allele-specific PCR. Either forward or reverse
primers were designed with specific mismatches in co-
dons 12, 13, and 60 of NRAS and in codon 12 of KRAS
(Supplementary Table S1). To improve specificity, an in-
tentional mismatch on the third nucleotide from the 3′
end was also included. Addition of the M13-tailed pri-
mers to the reaction led to the amplification of either
the internal control fragment alone (RAS WT) or concom-
itantly with the specific mutant allele (Supplementary
Tables S1 and S2). One hundred nanograms of DNA
were used in a final volume of 25 μL. Allele-specific
PCR specificity was assessed by amplifying multiple
DNA from healthy donors (RAS WT) and from patientsTable 2. Results of RAS mutational screening done by direct sequencing and allele-specific PCR at the
time of first presentation, as well as during the course of disease (Cont'd)Pt. ID First presentation Course of diseaseciation for
ournals.orOutcomeClinical C
  Cancer Research
 on October 8, 2012gFollow-up (mo)By seq By ASP By seq By ASP37 WT WT Deceased 28.5
39 WT WT Deceased 7
40 WT WT Deceased 14CML
38 WT WT N G13V (+3-25 mo)
N G12R (+42 mo)
N G13V (+3-42 mo)
N G12R (+12 mo)Progressed to AML;
deceased54Abbreviations: seq, sequencing; ASP, allele-specific PCR; N, NRAS; AML, acute myelogenous leukemia; K, KRAS.
*Patient with FLT3-ITD.
†Patients currently under chemotherapy.
‡Patient with the JAK2 V617F allele.ancer Research
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Published OnlineFirst April 14, 2010; DOI:10.1158/1078-0432.CCR-09-2112harboring mutant (mut) RAS alleles other than that speci-
fic for each allele-specific PCR. To determine allele-specific
PCR sensitivity, different amounts of mutDNA were spiked
into DNA WT and subjected to the corresponding allele-
specific PCR (except for the NRAS G13V mutation because
of the paucity of starting material).
Single-colony analysis. Peripheral blood mononuclear
cells were mixed with a methylcellulose culture medium
(MethoCult 4434, StemCell Technologies, Inc.) and sin-
gle colony–forming unit, granulocytes-macrophages
(CFU-GM), and burst-forming unit-erythroid (BFU-E)
were harvested in 40 μL of deionized water and heated
for 10 min at 95°C to release DNA. Allele-specific PCR
for the presence of the mutation previously identified
in the total DNA was done.
Statistical analyses. For the survival analyses, Kaplan-
Meier plots were generated using the elapsed time between
the date of the blood collection and death or the date of
the last follow-up, and the survival curves were compared
using log-rank testing. Unpaired one-tailed t test was used
to test the difference for continuous variables. The Fisher's
exact test was used to examine the association of two cat-
egorical variables. P < 0.05 was considered statistically sig-
nificant. The level of agreement between allele-specific
PCR and sequencing was assessed using the κ statistics,
considering substantial agreement if κ was >0.61. Analyses
were carried out using GraphPad Prism version 4.00 for
Windows (GraphPad Software; www.graphpad.com).
Results
Life expectation of patients with chronic myelomonocytic
leukemia is significantly shorter in MP-CMML than in
MD-CMML. The entire cohort of chronic myelomonocytic
leukemia patients included 23 men and 17 women, with a
median age of 74 years (range, 59-89 years). The median
follow-up was 28.3 months (range, 0-82.5 months), and
the median survival was 40 months (Fig. 1A). When pa-
tients were classified according to the WBC count into
MD-CMML (n = 22) and MP-CMML (n = 18), the median
WBC counts resulted 6.3 × 109/L and 15.8 × 109/L, respec-
tively. The median age was 73 years for MD-CMML and
75 years for MP-CMML patients. As predicted, the two
groups significantly differed for the absolute monocyte
count (median, 1.8 × 109/L in MD-CMML versus 3.7 ×
109/L in MP-CMML; P < 0.0001). Importantly, according
to the Kaplan-Meier estimates, patients with MP-CMML
had a significantly shorter median survival than those with
MD-CMML (14.5 months versus not reached; P = 0.003;
Fig. 1B).
RAS mutations prevail among patients with the MP-
CMML. We directly sequenced exons 1 and 2 of NRAS
and 1 to 3 of KRAS. Overall, at first presentation, no mu-
tation was detected in MD-CMML patients, whereas 4
(22.2%) of 18 MP-CMML patients were shown to harbor
a mutant allele (P = 0.033), the most frequent being the
NRAS G12D (Table 2). Notably, patient 30, who carried
the KRAS G12R mutation, was referred to our institutionwww.aacrjournals.org
American Asso Copyright © 2010 
clincancerres.aacrjDownloaded from as MP-CMML but had a previous history of MD-CMML;
unfortunately, no sample was available at the time of mye-
lodysplastic disease.
During follow-up, sequencing identified the NRAS G60E
and G12D substitutions in two patients (patients 8 and 33,
initially presenting as MD-CMML with RAS WT) after they
progressed to MP-CMML. With regard to the MP-CMML
group, sequencing detected the NRAS G12V mutation in
patient 24 36 months after the time of presentation and
the NRAS G12R and G13V alleles in patient 38 not at the
time of presentation as Philadelphia-positive CML but at
different times during the course of chronic myelomono-
cytic leukemia.
Because of the lack of data on the uncommon NRAS
G60E mutation at the time of its identification in patient
8 and to better understand its role in chronic myelomo-
nocytic leukemia evolution, we expressed the GFP/NRAS
WT, G60E, and G12D proteins in NIH3T3 cells and com-
pared their biochemical activity. After verifying by confo-
cal microscopy the expression of chimeric proteins in
transiently transfected cells (Supplementary Fig. S1A),
we determined the levels of active GTP-bound Ras. As
shown in Supplementary Fig. S1B, increased levels of
Ras-GTP were observed in cells expressing the mutant
proteins compared with the WT; in particular, the NRAS
G60E displayed intermediate levels of active Ras between
the WT and the G12D, in agreement with the recent pa-
per from Tyner et al. (33).
RAS mutations contribute to chronic myelomonocytic leu-
kemia progression: highly selective allele-specific PCR as a
powerful tool for early detection and tracking of disease evo-
lution. To gain further insights into the role of activated
RAS in chronic myelomonocytic leukemia evolution, we
set up an allele-specific PCR for each substitution identi-
fied by sequencing and rescreened all specimens. In our
experimental conditions, allele-specific PCR was able to
detect the presence of the corresponding mutant allele in
a mixture containing ∼1% to 2% of mutDNA in a back-
ground of DNA WT (Supplementary Fig. S2), whereas se-
quencing required about 20% (results not shown).
Allele-specific PCR confirmed all results obtained by se-
quencing. Yet, this method led to some interesting find-
ings summarized in Table 2 (the κ statistics indicated a
substantial agreement between allele-specific PCR and se-
quencing; κ = 0.6154). Overall, at presentation, a RASmu-
tation was detected in 2 (9%) of 22 MD-CMML and 6
(33.3%) of 18 MP-CMML patients (P = 0.065). Impor-
tantly, both MD-CMML patients presenting with a mutant
allele (patients 8 and 33) later on progressed to MP-
CMML; in our experimental conditions, a small amount
of the NRAS G60E allele was detected in patient 8's peri-
pheral blood withdrawn 22 months before disease pro-
gression (Fig. 2A), and the NRAS G12D allele was found
at low levels in the peripheral blood obtained from patient
33 at the time of first presentation (Fig. 2B). In this case,
three more samples were consecutively collected 13, 18,
and 25 months after the first withdrawal; of note, allele-
specific PCR allowed to monitor the increase of the levelClin Cancer Res; 16(8) April 15, 2010 2251
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Published OnlineFirst April 14, 2010; DOI:10.1158/1078-0432.CCR-09-2112of the oncogenic allele throughout the course of chronic
myelomonocytic leukemia (Fig. 2B and Supplementary
Fig. S3). Of the other three patients who experienced evo-
lution to myeloproliferative disease, patients 7 and 9 did
not display any of the alterations detectable by our assays,
whereas patient 31 was shown to harbor the FLT3-ITD
(results not shown).
Among MP-CMML patients, at presentation, allele-
specific PCR identified low levels of the NRAS G12D allele
in patients 22 and 32, who were both WT according to se-
quencing. During the follow-up, allele-specific PCR could
detect the NRAS G12V allele in patient 24 27 months after
the first presentation, 9 months earlier than sequencing
(Fig. 2C). In patient 38, who developed chronic myelomo-
nocytic leukemia as a second malignancy after remission
from Philadelphia-positive CML, in our experimental con-
ditions, no mutation was found at the time of CML
(Fig. 2D). Later on, allele-specific PCR allowed to accurate-
ly follow the consecutive occurrence of two distinct clones
harboring the NRAS G13V and G12R alleles, respectively.
In particular, allele-specific PCR identified the presence of
the G12R allele ∼30 months earlier than sequencing and
the persistence of the G13V mutation 17 months after se-
quencing could no longer detect it.
Finally, single colony analysis by allele-specific PCR was
carried out to assess in which progenitors the G12D muta-
tion occurred. We plated peripheral blood mononuclear
cells from patient 12 (MP-CMML with mutRAS by se-
quencing) and from patients 32 and 33 (respectively,
MP-CMML and MD-CMML at first presentation, with
RAS WT by sequencing) and found the mutation in colo-
ny-forming unit, granulocytes-macrophage, and BFU-E, ex-
ception made for patient 32, in which case no BFU-E grew.
Interestingly, as shown in Table 3, despite the relatively
low number of colonies analyzed, when comparing
patients 12 and 33 at time 0 the percentage of cells carry-
ing the G12D allele reflected the level of mutation found
by allele-specific PCR (Fig. 2B).
Chronic myelomonocytic leukemia patients with mutRAS
might have a trend for a shorter life expectation. We ana-
lyzed the impact of RAS mutations on survival of chronic
myelomonocytic leukemia patients. The median age was
74 years in WT and mutated groups. The group of patientsClin Cancer Res; 16(8) April 15, 2010
American Asso Copyright © 2010 
clincancerres.aacrjDownloaded from presenting with mutRAS by allele-specific PCR (n = 8) had
a significantly higher WBC count compared with the
group with RAS WT (n = 32; median, 13.6 × 109/L versus
9.7 × 109/L, respectively; P = 0.035). Importantly, al-
though median survivals of patients with mutRAS and
RAS WT were not significantly different, possibly because
of the limited sample size, a trend for a shorter life expec-
tation, more evident after the first 2 years of follow-up,
is suggested for patients harboring a RAS mutation
in comparison with WT patients (median, 26.5 versus
42 months; Fig. 3).
Discussion
Inclusion of chronic myelomonocytic leukemia into the
new category of mixed myelodysplastic syndrome/myelo-
proliferative neoplasms (12) did not represent a conclu-
sive solution with regard to the diverse clinical
phenotypes of this malignancy. Indeed, because the prog-
nostic significance of the distinction between MD-CMML
and MP-CMML is still debated upon (5–10) and because
the cutoff value of WBC to identify such groups is arbi-
trary, no general consensus has been reached on this sub-
classification dilemma. In agreement with previous reports
(5, 7–9), our results support its prognostic value because
MP-CMML patients had a significantly shorter survival
than those with myelodysplastic disease.
We then investigated the biological implication of the
myelodysplastic/myeloproliferative distinction, focusing
in particular on the role of RAS mutations in chronic
myelomonocytic leukemia evolution. To this aim, we con-
ducted a longitudinal monitoring of chronic myelomono-
cytic leukemia course first by sequencing and then by
allele-specific PCR. In fact, among the various assays deve-
loped for early detection of specific mutations, tracking of
disease progression, and evaluation of molecular response
to therapy, which are crucial issues in clinical practice,
allele-specific PCR represents a simple, fast, and sensitive
method (35, 36). Direct sequencing detected a significant-
ly higher incidence of RAS mutations in MP-CMML pa-
tients, consistent with previous reports (1, 5, 7–9, 14).
Next, for each mutation identified, we set up a highly se-
lective yet simple and low-cost allele-specific PCR, which,ciation for Cancer Researc
 on October 8, 2ournals.orgFig. 1. Kaplan-Meier survival
curves of chronic myelomonocytic
leukemia patients. A, overall
survival of all 40 patients with
chronic myelomonocytic
leukemia. B, survival of chronic
myelomonocytic leukemia
patients grouped by WBC count
(<13 × 109/L or ≥13 × 109/L).
The log-rank test was used to
analyze differences between the
survival curves.Clinical Cancer Research
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more sensitive than sequencing and did not require expen-
sive equipment and proprietary reagents. Accordingly, at
the time of first presentation or referral, allele-specific
PCR detected a higher percentage of patients carrying a
RAS mutation compared with sequencing. Moreover,
allele-specific PCR allowed identification of a mutRAS
allele in MD-CMML and MP-CMML patients, whereas
sequencing only did in the latter group. Importantly, mo-
lecular monitoring done on matched presentation/follow-
up pair samples from both MD-CMML patients presenting
with a RAS mutation (patients 8 and 33) who experiencedwww.aacrjournals.org
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time of myelodysplastic diseaselow levels of the mutations
that became predominant in the myeloproliferative phase.
Albeit few cases of MD-CMML progressing to myeloprolif-
erative disease have been reported (1, 2, 8, 11), to the best
of our knowledge, this is the first study documenting the
appearance of RASmutations in concomitance with chron-
ic myelomonocytic leukemia evolution.
Allele-specific PCR was also able to detect the presence
of a mutant allele earlier than sequencing during the
course of myeloproliferative disease (patients 24 and
38). Indeed, in the case of patient 24, allele-specific PCRFig. 2. Allele-specific PCR unveils the presence of RAS mutations much earlier than sequencing in a number of cases and provides evidence for the
contribution of RAS mutations acquisition in chronic myelomonocytic leukemia progression to myeloproliferative phase. For each sample, the diagnosis is
reported along with the results of RAS sequencing. A, allele-specific PCR for the NRAS G60E substitution (GGA→GAA) identified the mutant allele in
the peripheral blood of patient 8 already at the time of presentation (0 mo; MD-CMML), whereas sequencing could detect it only after progression to
MP-CMML (+22 mo). ctrl, control; Pt., patient. B, in patient 33 allele-specific PCR allowed to follow the increase of the G12D allele (GGT→GAT) throughout
the course of disease, from MD-CMML to blunt MP-CMML, whereas sequencing suggested the presence of the mutation only 13 mo after presentation.
Thirty-eight cycles of amplification were done in place of the canonical 39 to enhance the differences between the various samples. C, in patient 24,
allele-specific PCR unveiled the presence of low levels of the NRAS G12V allele (GGT→GTT) 27 mo after the first increase of WBC to more than the 13 × 109/L
threshold, whereas sequencing could detect the substitution only after further 9 mo (for more details on the clinical situation of patient 24, refer to the
Discussion section). D, allele-specific PCR allowed to follow the consecutive occurrence of two clones harboring the NRAS G13V (GGT→GTT) and G12R
mutations (GGT→CGT), respectively, earlier than sequencing in patient 38, who had a previous diagnosis of Philadelphia-positive CML (0 mo).Clin Cancer Res; 16(8) April 15, 2010 2253
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sample obtained during hydroxyurea (HU) treatment
27 months after the first withdrawal that coincided with
the initial increase of WBC to more than the 13 × 109/L
threshold. Because allele-specific PCR for the G12V allele
has shown the lowest sensitivity out of the six allele-
specific PCR developed, we cannot rule out the possibility
that the mutated clone was already present at very low le-
vels at the time of the first withdrawal. We may also spec-
ulate that HU reduced the mutated clone, thus preventing
sequencing but not allele-specific PCR (which is far more
sensitive) from identifying the G12V allele at the time of
the second sample.
Finally, allele-specific PCR provided evidence for the
occurrence of the NRAS G12D mutation in a progenitor
common to the granulocytic/monocytic and erythroid
precursors and in a percentage of cells that reflected the
level of mutation detected in total DNA. In these regard,
it would be interesting to further explore whether the
mutation arises in the stem cells compartment because
it was shown very recently in mouse models of myelo-
proliferative diseases (37, 38). Altogether, our findings
suggest the occurrence of a RAS mutated clone in chronic
myelomonocytic leukemia that eventually expanded, ta-
king proliferative advantage on the RAS WT cells, and fi-
nally led to disease progression along with establishment
of a stable myeloproliferative phenotype, which is associ-
ated with worse outcome. Notably, in agreement with the
findings from the largest chronic myelomonocytic leuke-
mia population ever analyzed (15), also in our cohort of
patients the presence of mutRAS significantly correlated
with higher WBC counts, whereas association with a
shorter survival did not reach statistical significance pos-
sibly because of the limited sample size.
From a molecular point of view, albeit the mechanisms
at the basis of chronic myelomonocytic leukemia patho-
genesis are not fully understood, evidences from in vivo
studies along with analysis of patient series suggest that
multiple genetic events may contribute to disease develop-
ment, especially in the proliferative forms. In particular,
although RAS mutations seem to be the most commonly
identified genetic aberration in MP-CMML, the FLT3-ITDClin Cancer Res; 16(8) April 15, 2010
American Asso Copyright © 2010 
clincancerres.aacrjDownloaded from (28) and the JAK2 V617F substitution (29, 30) have also
been found in a minority of patients. Indeed, we detected
the FLT3-ITD in a case of MD-CMML who rapidly pro-
gressed to MP-CMML and then to acute leukemia (patient
31) and the JAK2 V617F substitution in two cases classi-
fied as MP-CMML at the time of first presentation (pa-
tients 23 and 35; results not shown). Interestingly, the
cumulative median survival of all patients (n = 11) pre-
senting with a genetic aberration (mutRAS, FLT3-ITD, or
JAK2 V617F, which are mutually exclusive) compared with
those without (n = 29) was shorter (25 months versus not
reached), and the difference reached statistical significance
(P = 0.049). Given that specific inhibitors are currently un-
der investigation for these aberrations (39, 40), their de-
tection is of clinical relevance.
Based on these data, it may be hypothesized that the
myelodysplastic/myeloproliferative distinction reflects
different molecular subtypes of chronic myelomonocytic
leukemia. In particular, as far as the MD-CMML is
concerned, it might be supposed that pathogenetic events
other than RAS mutations are responsible for its estab-
lishment and that acquisition of a secondary event like
a RAS mutation or, in a minority of patients, the FLT3-
ITD or the JAK2 V617F substitution causes the myelopro-
liferative phenotype. One possible candidate could be
TET2, whose mutations have been recently identified in
a wide spectrum of myeloid malignancies (19–26), lead-
ing to hypothesize that they are an early event in
hematopoietic differentiation and that at least one addi-
tional event is required to determine the disease pheno-
type (19, 27). Moreover, Gelsi-Boyer et al. (14) have
recently identified RUNX1 alterations in a series of
chronic myelomonocytic leukemia patients with MD-
CMML and MP-CMML, whereas RAS mutations were ab-
sent in the former group. These results, together with the
observation that RAS and RUNX1 aberrations were not
mutually exclusive, led the authors to speculate that
RUNX1 alterations might be responsible for dysplasiaFig. 3. Kaplan-Meier survival curves of patients with chronic
myelomonocytic leukemia as a function of RAS mutations. The log-rank
test was used to analyze differences between the survival curves.Table 3. Results of the single-colony analysis
carried out by allele-specific PCR for the NRAS
G12D substitutionPt. No. of NRAS G12D+ colonies/totCFU-GM BFU-E12 8/8 10/10
32 0/8 No growth
33 4/6 2/7Abbreviations: tot,, total; CFU-GM, colony-forming unit,
granulocytes-macrophage.Clinical Cancer Research
 ciation for Cancer Research
 on October 8, 2012ournals.org
RAS Mutations in CMML
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Tyner et al. (41) found RAS mutations in MD-CMML and
MP-CMML. One possible explanation for this discrepancy
may be the different sensitivity of themethods used. Unfor-
tunately, none of the two groups conducted a longitudinal
analysis, neither gave information on the disease course of
MD-CMML patients. Clearly, to elucidate the biology of
chronic myelomonocytic leukemia, further investigations
on larger groups of patients are needed.
In conclusion, albeit not all patients who experienced
progression to myeloproliferative phase nor all patients
presentingwith a de novomyeloproliferative phenotype har-
bored a mutRAS allele, our results suggest the negative
impact of RAS mutations on chronic myelomonocytic leu-
kemia course. Therefore, also in light of the ongoing studies
aimed at identifying effective Ras inhibitors (42–45), we
believe that detection of RAS mutations in chronic myelo-
monocytic leukemia could be of clinical relevance. We pro-
pose screening by highly selective yet simple and low-cost
allele-specific PCR to be implemented as a standard inwww.aacrjournals.org
American Asso Copyright © 2010 
clincancerres.aacrjDownloaded from chronic myelomonocytic leukemia diagnostics and disease
monitoring to help clinical decision making.
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